FibroBiologics, Inc.

What they do

FibroBiologics develops fibroblast-based cell therapies for chronic diseases including wound healing, psoriasis, multiple sclerosis, degenerative disc disease, certain cancers, and potential longevity applications. Its lead candidates are CYWC628 for wound healing, CYPS317 for psoriasis, CYMS101 for multiple sclerosis, and CybroCell for degenerative disc disease. The company is development-stage; no product has been approved or commercialized.

Revenue drivers

• CYWC628 (wound healing) — Most advanced candidate; after completing IND-enabling preclinical studies, the company initiated a twelve-week Phase 1/2 trial in Australia in diabetic foot ulcers, but generates no revenue today.
• CYPS317 (psoriasis) — An IND application was filed with the FDA on December 30, 2025, and is being updated based on FDA feedback; no revenue.
• CYMS101 (multiple sclerosis) — A completed five-participant Phase 1 study in Mexico assessed safety with no treatment-related adverse events reported; the company plans a U.S. IND in 2026 and seeks a strategic partner. No revenue.
• CybroCell (degenerative disc disease) — Received FDA IND clearance in 2018 conditional on approval of its master cell bank; development-stage with no revenue.

Recent performance

The company has no product revenue and has been loss-making. Net losses were $5.1 million in 2022, $16.5 million in 2023, $11.2 million in 2024, and $18.6 million in 2025, with diluted EPS of -$0.18, -$0.68, -$0.34, and -$0.42, respectively. Operating cash use grew from $4.1 million in 2022 to $6.4 million in 2023, $11.9 million in 2024, and $16.4 million in 2025. At June 30, 2026 the balance sheet showed total assets of $7.9 million, total liabilities of $3.3 million, shareholder equity of $4.6 million, and cash and equivalents of $3.5 million.

Strategy

Management is advancing fibroblast-based therapies through preclinical and early clinical work, with CYWC628 already in a twelve-week Phase 1/2 trial in Australia and an FDA IND for CYPS317 filed in December 2025 that is being updated. It plans to file a U.S. IND for CYMS101 in 2026 after CYPS317 clearance and expects to seek a strategic partner for CYMS101 before or after the Phase 1/2 study. For CybroCell, the company reported using the CYWC628 spheroid master cell bank to manufacture a modified drug product for degenerative disc disease. The company has also entered material agreements and sold equity in 2026, raising capital to fund these programs.

Risks

• No approved products or revenue — All candidates remain preclinical or in early clinical testing, so the company has no product revenue and depends on financing to operate.
• Thin cash relative to cash burn — With $3.5 million of cash and equivalents at June 30, 2026 and operating cash use of $16.4 million in 2025, the company likely needs further financing to fund ongoing trials.
• Clinical and regulatory uncertainty — The CYPS317 IND filed on December 30, 2025 is being updated based on FDA feedback, and CybroCell's 2018 IND clearance was conditional upon master cell bank approval, so timelines may slip.
• Listing-rule and dilution risk — The company disclosed a delisting notice or listing-rule failure on July 24, 2026, and has sold unregistered equity in June and September 2026, which can dilute existing holders.

Outlook

Management points to the ongoing Australian Phase 1/2 trial of CYWC628 for diabetic foot ulcers and an updated FDA submission for CYPS317 as near-term milestones. It plans a U.S. IND for CYMS101 in 2026, contingent on CYPS317 clearance, and expects to seek a strategic partner for CYMS101. The company has not provided revenue guidance, as it has no approved products.